Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. (Q51506177)

6 April 2018

title

Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. (English)

1 reference

6 April 2018

author name string

C Jerome

series ordinal

1

1 reference

6 April 2018

M Missbach

series ordinal

2

1 reference

6 April 2018

R Gamse

series ordinal

3

1 reference

6 April 2018

language of work or name

English

0 references

publication date

10 February 2011

1 reference

6 April 2018

Osteoporosis International

published in

1 reference

6 April 2018

volume

22

1 reference

6 April 2018

issue

12

1 reference

6 April 2018

page(s)

3001-3011

1 reference

6 April 2018

https://scigraph.springernature.com/pub.10.1007/s00198-011-1529-x

exact match

0 references

cites work

Update on osteoporosis therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Update of current therapeutic options for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

The gastrointestinal tolerability and safety of oral bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Adherence and persistence: impact on outcomes and health care resources

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Future anti-catabolic therapeutic targets in bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1529-X

Primate models of osteoporosis

21 January 2018

1 reference

12 December 2020

Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)

1 reference

12 December 2020

Revised Guide for the Care and Use of Laboratory Animals available. American Physiological Society

1 reference

12 December 2020

Osteonecrosis of the jaw: more research needed

1 reference

12 December 2020

Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K

1 reference

12 December 2020

Anabolic Agents for Osteoporosis : What is Their Likely Place in Therapy?

1 reference

12 December 2020

Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo

1 reference

12 December 2020

10.1007/S00198-011-1529-X

Identifiers

DOI

1 reference

6 April 2018

1 reference

6 April 2018